Equity · Healthcare
Viking Therapeutics, Inc. (VKTX) perpetual futures
VKTX perpetual futures on 11 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade VKTXUSDT.
Viking Therapeutics is a clinical-stage biopharmaceutical company developing oral therapies for metabolic and endocrine diseases, including VK2809 for NASH and NAFLD.
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:VKTX
Loads TradingView's third-party widget (about 1 MB) on demand.
Trading data
Perpetual market activity
11/11 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
11 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Ourbit | Trade | VKTX/USDT | Trading | $28.14 | 0.0% APR 0.000% every 8h | +17.7 bps | $82.4K | $561.3K | $121.5K | USDT | 20x | |
 Bybit | Trade | VKTX/USDT | Trading | $28.16 | 0.0% APR 0.000% every 8h | +28.4 bps | $137.1K | $500.8K | $28.1K | USDT | 25x | |
 Binance | Trade | VKTX/USDT | Trading | $28.11 | 0.0% APR 0.000% every 8h | +17.7 bps | $28K | $274K | $56.7K | USDT | - | |
 XT.com | Trade | VKTX/USDT | Trading | $28.10 | +11.0% APR +0.010% every 8h | +17.7 bps | $55.5K | $207.5K | - | USDT | 20x | |
 HTX | Trade | VKTX/USDT | Trading | $28.12 | 0.0% APR 0.000% every 8h | +216.9 bps | $0 | $135.8K | $5.4K | USDT | - | |
 MEXC | Trade | VKTX/USDT | Trading | $28.09 | 0.0% APR 0.000% every 8h | +17.7 bps | $52.7K | $105.3K | $11.7K | USDT | 20x | |
 Bitget | Trade | VKTX/USDT | Trading | $28.12 | 0.0% APR 0.000% every 8h | +19.2 bps | $189.6K | $75.5K | $70.7K | USDT | 20x | |
 Bitunix | Trade | VKTX/USDT | Trading | $28.14 | +12.1% APR +0.011% every 8h | +21.3 bps | $51.1K | $68.6K | $7.2K | USDT | 20x | |
 Gate.io | Trade | VKTX/USDT | Trading | $28.12 | 0.0% APR 0.000% every 8h | +99.4 bps | $11.7K | $2.3K | $4.1K | USDT | 20x | |
 BingX | Trade | VKTX-USDT | Trading | $28.12 | -5.5% APR -0.00500% every 8h | +24.8 bps | $33.2K | $662.8K | - | USDT | - | |
 LBank | Trade | VKTX/USDT | Trading | $28.11 | 0.0% APR 0.000% every 8h | +17.7 bps | $343.2K | $639.6K⚠ | $23.1 | USDT | 20x |
Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 10 of 11 venues absorb $10k · Typical cost: +30.9 bps – +43.9 bps
No fresh book data: HTX
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
VKTXTightest spread
VKTXHighest volume
VKTXFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $82 |
| 12-month target range (low – high) | $34 – $120 |
| Ratings in the provider's consensus | 24 |
Price targets as of 2026-11-12
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 5 | 14 | 2 | 0 | 0 |
| Oct 2026 | 5 | 14 | 2 | 0 | 0 |
| Sep 2026 | 5 | 13 | 2 | 0 | 0 |
| Aug 2026 | 5 | 13 | 2 | 0 | 0 |
| Jul 2026 | 5 | 13 | 2 | 0 | 0 |
| Jun 2026 | 5 | 13 | 2 | 0 | 0 |
| May 2026 | 5 | 13 | 2 | 0 | 0 |
| Apr 2026 | 5 | 12 | 2 | 0 | 0 |
| Mar 2026 | 5 | 12 | 2 | 0 | 0 |
| Feb 2026 | 5 | 12 | 1 | 0 | 0 |
| Jan 2026 | 5 | 12 | 1 | 0 | 0 |
| Dec 2025 | 5 | 12 | 1 | 0 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
VKTX-PERPPrice performance
11Insider activity
FY2026 Q3Insider transactions
25Viking Therapeutics director Dorothy Elizabeth Kelly-Gemmell received two grants on Aug 1, 2026: 40,800 stock options at a $31.74 strike price and 6,333 common shares, disclosed in a Form 4 filed Aug 7, 2026.
Viking Therapeutics reported a Form 3 for insider Dorothy Elizabeth Kelly-Gemmell dated 2026-08-01: no shares acquired or disposed, 0 shares of common stock owned after.
Viking Therapeutics director and CEO Brian Lian received an award of 221,667 common shares and sold 148,517 common shares at $33.3153, leaving 2,572,441 shares owned.
Viking Therapeutics CFO Greg Zante received a grant of 31,667 common shares (A-Award) and sold 21,217 common shares at $33.4704 (S-Sale). He held 212,204 shares after the sale.
Viking Therapeutics COO Marianna Mancini received a grant of 31,667 common shares and sold 18,217 shares at $33.47, leaving 422,760 shares owned.
Viking Therapeutics officer Hubert C Chen received a grant of 190,000 stock options (right to buy) at an exercise price of $31.27, per a Form 4 filed 2026-06-03.
Viking Therapeutics (VKTX) reported a Form 3 filing by Chen Hubert C dated 2026-06-03, an initial statement of beneficial ownership. It lists a single 2026-06-01 entry of 0 shares of common stock at $0.00, with no shares owned afterward.
Viking Therapeutics officer Neil William Aubuchon (Chief Commercial Officer) reported an open-market purchase of 4,475 common shares at $33.50 on 2026-03-10, leaving 4,475 shares owned.
Viking Therapeutics officer Neil W. Aubuchon received a stock option award (A) for 180,000 shares at $31.76 on 2026-01-12, a grant of compensation rather than an open-market purchase.
Neil William Aubuchon, an insider at Viking Therapeutics (VKTX), filed an initial Form 3 reporting no shares or transactions in common stock as of the 2026-01-26 filing date.
Viking Therapeutics CFO Greg Zante received awards of 73,049 common shares and 91,000 stock options, and sold 57,661 shares at $32.09-$34.24.
Viking Therapeutics COO Marianna Mancini received 73,049 shares via two stock awards and sold 45,561 shares in two open-market sales at $32.29-$33.37, leaving 421,290 shares.
Filings
34 · Latest SEC filingsViking Therapeutics reported a Form 3 for insider Dorothy Elizabeth Kelly-Gemmell dated 2026-08-01: no shares acquired or disposed, 0 shares of common stock owned after.
Viking Therapeutics director Dorothy Elizabeth Kelly-Gemmell received two grants on Aug 1, 2026: 40,800 stock options at a $31.74 strike price and 6,333 common shares, disclosed in a Form 4 filed Aug 7, 2026.
Viking Therapeutics CFO Greg Zante received a grant of 31,667 common shares (A-Award) and sold 21,217 common shares at $33.4704 (S-Sale). He held 212,204 shares after the sale.
Viking Therapeutics COO Marianna Mancini received a grant of 31,667 common shares and sold 18,217 shares at $33.47, leaving 422,760 shares owned.
Viking Therapeutics director and CEO Brian Lian received an award of 221,667 common shares and sold 148,517 common shares at $33.3153, leaving 2,572,441 shares owned.
Viking Therapeutics officer Hubert C Chen received a grant of 190,000 stock options (right to buy) at an exercise price of $31.27, per a Form 4 filed 2026-06-03.
Viking Therapeutics (VKTX) reported a Form 3 filing by Chen Hubert C dated 2026-06-03, an initial statement of beneficial ownership. It lists a single 2026-06-01 entry of 0 shares of common stock at $0.00, with no shares owned afterward.
Viking Therapeutics officer Neil William Aubuchon (Chief Commercial Officer) reported an open-market purchase of 4,475 common shares at $33.50 on 2026-03-10, leaving 4,475 shares owned.
Neil William Aubuchon, an insider at Viking Therapeutics (VKTX), filed an initial Form 3 reporting no shares or transactions in common stock as of the 2026-01-26 filing date.
Viking Therapeutics officer Neil W. Aubuchon received a stock option award (A) for 180,000 shares at $31.76 on 2026-01-12, a grant of compensation rather than an open-market purchase.
Transcripts
Earnings callsFY2026 Q32026-10-28
Earnings calls
AI summary
positiveViking reported Q3 2026 financials and pipeline updates. Both Phase III VANQUISH studies of subcutaneous VK2735 in obesity and obesity with type 2 diabetes are fully enrolled and advancing, with first patients expected to enter the extension period in early 2027. In October, the company initiated the Phase III SUNRISE program for oral VK2735. Positive Part 1 maintenance data showed weight loss retention of 82%-97% with every-other-week or monthly dosing versus 61% for placebo, and a 17.5 mg weekly cohort lost about 22% at 33 weeks with no plateau. Part 2, evaluating oral and additional subcutaneous maintenance regimens, has been initiated. The amylin agonist VK3019 single ascending dose study is expected to complete by year-end, with a multiple ascending dose study planned for Q1 2027. The company raised approximately $575 million gross in concurrent offerings and ended the quarter with $960 million in cash.
Key takeaways
- Both VANQUISH Phase III trials of subcutaneous VK2735 (obesity; obesity with type 2 diabetes) are fully enrolled and proceeding according to plan; first patients are expected to enter the extension period in early 2027.
- Oral VK2735 Phase III SUNRISE program was initiated in October 2026, with two studies dosing once daily for 68 weeks at 27.5 mg, 35 mg, 55 mg or placebo.
- In the Part 1 maintenance study, every-other-week regimens retained 83%-97% of weight loss and monthly regimens 82%-90% at week 33, versus 61% for placebo; maintenance-phase GI adverse events were not meaningfully different from placebo.
- A 17.5 mg weekly cohort dosed for 33 weeks achieved mean weight loss of approximately 22% with no observed plateau; at week 21, active groups lost roughly 16%-19%.
- VK3019 amylin agonist single ascending dose study is expected to complete by year-end, and a multiple ascending dose study is planned to start in Q1 2027; Part 2 maintenance results are expected in 2027.
Financial highlights
- Q3 2026 R&D expense was $166.8 million versus $90 million in Q3 2025.
- Q3 2026 G&A expense was $20.3 million versus $8.6 million in Q3 2025.
- Q3 2026 net loss was $183.2 million, or $1.55 per share, versus a net loss of $90.8 million, or $0.81 per share, in Q3 2025.
- Cash, cash equivalents and short-term investments were $960 million at September 30, 2026, versus $706 million at December 31, 2025, including approximately $550 million of net proceeds from the recent financing.
Guidance
- Cash usage is expected to average around $100 million per quarter company-wide, with some quarters higher or lower.
- G&A is expected to be fairly flat near term, with a possible pickup later toward commercialization.
- VK3019 single ascending dose study is expected to complete later this quarter; a multiple ascending dose study is planned to initiate in Q1 2027.
- Part 2 maintenance study results are expected in 2027.
Q&A themes
- Differentiation of VK2735 via dual subcutaneous/oral formulations and weekly, every-other-week or monthly dosing flexibility.
- Rationale for the narrower oral Phase III dose range (27.5-55 mg) and 4-week titration blocks, including tablet burden and gross margin considerations.
- Whether maintenance extension data could be included in an initial regulatory filing or would come as a later supplement (described as TBD, with a supplement seen as more likely).
- Potential of the amylin agonist VK3019 as a monotherapy or in combination with VK2735, and the target profile for the multiple ascending dose study.
Risks
- The company declined to project VANQUISH Phase III weight-loss results based on earlier data.
- Inclusion of VANQUISH extension maintenance data in the initial regulatory submission versus a later supplement remains undetermined.
- Part 2 oral maintenance outcomes are difficult to predict due to the exposure change when transitioning from weekly subcutaneous to daily oral dosing.
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.Company data
Company intelligence
Updated: Nov 2, 2026, 08:21 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Brian Lian
- Employees
- 53
- IPO date
- Apr 28, 2015
- Country
- US
- Exchange
- NASDAQ Capital Market
Rating factors
- Return on equityi
- 1
- Return on assetsi
- 1
- Debt to equityi
- 2
- Price to earningsi
- 1
- Price to booki
- 1
Company press releases
Market cap history
Not comparable with the headline: the provider's history counts about 118.49M shares, the headline 127.52M. Shown as the provider reports it.
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.01% | 3.8M |
| XBI | 0.9% | 3.7M |
| VB | 0.05% | 2.7M |
| VBK | 0.11% | 1.5M |
| FZAHX | 0.11% | 1.5M |
| VXF | 0.05% | 1.4M |
| TWHIX | 0.73% | 1.2M |
| FDSCX | 0.26% | 704.1K |
| FSMAX | 0.05% | 679.1K |
| SCHA | 0.08% | 662.8K |
| FSPHX | 0.26% | 645.3K |
| FBTAX | 0.75% | 642.1K |
Analyst track record
How the analysts covering VKTX have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 103 | 355 |
| Analysts | 22 | 28 |
| Buy / hold / sell | 100 / 3 / 0 | 345 / 10 / 0 |
| Upgrades / downgrades / initiations | 0 / 0 / 5 | 0 / 0 / 15 |
| Price targets hit / missed | 0 / 90 (0%) | 0 / 296 (0%) |
| Avg. return after a rating (TipRanks) | -69.6% | -68.4% |
| Best / worst call | -21.1% / -78.5% | -4.1% / -83.6% |
After buy calls on this stock: median 21-day move -2.3% vs S&P 500 -4.5% (n = 342)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Joon LeeUBS22% hit rate on this stock · 9 targets measuredBuytarget $94.00Oct 29, 2026
- Jay OlsonOppenheimer20% hit rate on this stock · 20 targets measuredBuytarget $120Oct 29, 2026
- Annabel SamimyStifel Nicolaus14% hit rate on this stock · 14 targets measuredBuytarget $95.00Oct 29, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Oct 30, 2026 | Naz RahmanMaxim GroupOct 30, 2026 | BuyReiterated | $70.00↗ | article ↗ |
| Oct 30, 2026 | Edward NashCanaccord GenuityOct 30, 2026 | BuyMaintained | $118↗ | article ↗ |
| Oct 29, 2026 | William WoodB. Riley SecuritiesOct 29, 2026 | BuyMaintained | $85.00↗ | article ↗ |
| Oct 29, 2026 | Michael UlzMorgan StanleyOct 29, 2026 | BuyReiterated | $95.00↗ | article ↗ |
| Oct 29, 2026 | Jay OlsonOppenheimerOct 29, 2026 | BuyMaintained | $120↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 9, 2026 · 103 ratings
Frequently asked questions
Where can I trade VKTX perpetual futures?
Viking Therapeutics, Inc. (VKTX) perpetual futures trade on 11 crypto venues, including BingX, LBank, Ourbit. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade VKTX around the clock?
Yes. Unlike the underlying stock, VKTX perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on VKTX perpetuals?
Right now the VKTX perp funding rate is 0.0% annualized (venue median), ranging from -5.5% to +12.1% across 11 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the VKTX perp price compare to the Viking Therapeutics, Inc. stock?
The venue-median VKTX perp mark is $28.1 versus a reference stock price of $28.1, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a VKTX perpetual future?
A VKTX perpetual is a derivative that tracks the price of Viking Therapeutics, Inc. with no expiry date. It lets you take long or short exposure to Viking Therapeutics, Inc. on crypto venues, around the clock.
What is VKTXUSDT perpetual?
VKTXUSDT is the symbol most crypto exchanges use for the Viking Therapeutics, Inc. perpetual settled in USDT (Tether). It tracks the VKTX share price through an index, trades 24/7 with leverage and never expires.
Embed this asset
<a href="https://perpequities.com/stocks/vktx-perp"><img src="https://perpequities.com/badge/vktx-perp.svg" width="240" height="64" alt="VKTX perpetuals · perpequities.com" loading="lazy"></a>